deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03721965

Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects

An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Combination With Corticosteroids for the Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in Pediatric Subjects

Sponsor: Incyte Corporation

Conditions Acute Graft-versus-host Disease
Interventions Corticosteroids Itacitinib
Updated 13 times since 2018 Last updated: Oct 20, 2025 Started: Dec 31, 2019 Primary completion: Feb 17, 2020 Completion: Feb 17, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The study was terminated due to insufficient efficacy in a separate phase III study

Other terminated trials from Incyte Corporation

More terminations from Incyte Corporation

This PHASE1/PHASE2 trial investigates Acute Graft-versus-host Disease and is currently terminated or withdrawn. Incyte Corporation leads this study, which shows 13 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Nov 2018 – ~Jul 2019 · 8 months · monthly snapshot~Jul 2019 – ~Dec 2019 · 5 months · monthly snapshot~Dec 2019 – ~Mar 2020 · 3 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2022 · 13 months · monthly snapshot~Apr 2022 – ~Mar 2023 · 11 months · monthly snapshot~Mar 2023 – ~Jul 2024 · 16 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshot~Dec 2025 – present · 7 months · monthly snapshot

Change History

13 versions recorded

  1. Dec 2025 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Sep 2025 — Dec 2025 [monthly]

    Terminated PHASE1/PHASE2

  3. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Mar 2023 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

▶ Show 8 earlier versions

  1. Apr 2022 — Mar 2023 [monthly]

    Terminated PHASE1_PHASE2

  2. Mar 2021 — Apr 2022 [monthly]

    Terminated PHASE1_PHASE2

  3. Jan 2021 — Mar 2021 [monthly]

    Terminated PHASE1_PHASE2

  4. Apr 2020 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

    Status: Recruiting → Terminated

  5. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE1_PHASE2

  6. Dec 2019 — Mar 2020 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jul 2019 — Dec 2019 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  8. Nov 2018 — Jul 2019 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Incyte Corporation
Data source: Incyte Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aachen, Germany , Aurora, United States , Barcelona, Spain , Birmingham, United Kingdom , Bologna, Italy , Bristol, United Kingdom , Catania, Italy , Cleveland, United States , Duarte, United States , Durham, United States and 24 more locations